Olesen KKW, Pareek M, Madsen M, et al. - Researchers compared 10-year clinical outcomes following treatment with Endeavor zotarolimus-eluting (ZES) or Cypher sirolimus-eluting coronary stents (SES) in patients with diabetes vs non-diabetes patients. Randomization of 1,162 patients to ZES (169 with diabetes) and of 1,170 patients to SES (168 with diabetes) was done. A combined endpoint of mortality or myocardial infarction, and the individual endpoints of death, myocardial infarction, and revascularization, were assessed as endpoints. Findings revealed similar performances of SES and ZES at 10 years in patients with and without diabetes. Although diabetes patients with ZES exhibited a more prevalence of coronary revascularization, this may, partially, have been associated with the angiographic follow-up that was provided to a subgroup of diabetes patients.